Amitriptyline revisited - pharmacogenetic implications in antidepressant treatment

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: MIFSUD BUHAGIAR, Luana (University of Malta, Pharmacy, Lija, Malta)
  • Co-author(s): Luana Mifsud Buhagiar: Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta;, Malta Medicines Authority, San Gwann, Malta
    Godfrey LaFerla: Department of Surgery, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
    Anthony Serracino Inglott: Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta;, Malta Medicines Authority, San Gwann, Malta
    Anton Grech: Department of Psychiatry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
  • Abstract:

    Methods

    Following informed consent, outpatients receiving amitriptyline for depression have blood and/or saliva samples taken for HPLC determination of the metabolite to parent drug concentration ratio and testing of CYP2D6 and CYP2C19 concurrently, allowing observation of potential additive effects.  Recommendations, in line with gene/drug

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login